Arab Journal of Gastroenterology最新文献

{"title":"Adherent-invasive Escherichia coli LF82 disrupts the tight junctions of Caco-2 monolayers","authors":"Sumei Sha ,&nbsp;Huijun Gao ,&nbsp;Hong Zeng ,&nbsp;Fenrong Chen ,&nbsp;Junxiu Kang ,&nbsp;Yan Jing ,&nbsp;Xin Liu ,&nbsp;Bin Xu","doi":"10.1016/j.ajg.2024.07.011","DOIUrl":"10.1016/j.ajg.2024.07.011","url":null,"abstract":"<div><h3>Background and study aims:</h3><div>Adherent invasive <em>Escherichia coli</em> (AIEC) are enriched in IBD (inflammatory bowel disease) patients, but the role and mechanism of AIEC in the intestinal epithelial barrier is poorly defined. We evaluated the role of the AIEC strain <em>E. coli</em> LF82 in vitro and investigated the role of Th17 in this process.</div></div><div><h3>Material and methods:</h3><div>After coincubation with AIEC, the epithelial barrier integrity was monitored by epithelial resistance measurements. The permeability of the barrier was evaluated by TEER (<em>trans</em>-epithelial electrical resistance) and mucosal-to-serosal flux rate. The presence of interepithelial tight junction proteins ZO-1 and Claudin-1 were determined by immunofluorescence and western blot analysis. Cytokines in the cell culture supernatant were assayed by enzyme-linked immunosorbent assay (ELISA).</div></div><div><h3>Results:</h3><div>AIEC infection decreased TEER and increased the mucosal-to-serosal flux rate of Lucifer yellow in the intestinal barrier model in a time- and dose-dependent manner. AIEC infection decreased the expression and changed the distribution of ZO-1 and claudin-1. It also induced the secretion of cytokines such as TNF-α and IL-17.</div></div><div><h3>Conclusion:</h3><div>AIEC strain <em>E. coli</em> LF82 increased the permeability and disrupted the tight junctions of the intestinal epithelial barrier, revealing that AIEC plays an aggravative role in the inflammatory response.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 4","pages":"Pages 383-389"},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ammonia in liver diseases: A glimpse into the controversies and consensus","authors":"George Sarin Zacharia,&nbsp;Anu Jacob","doi":"10.1016/j.ajg.2024.07.016","DOIUrl":"10.1016/j.ajg.2024.07.016","url":null,"abstract":"<div><div>Ammonia is a byproduct of the metabolism of nitrogen-containing micro and macromolecules. The key source of bodily ammonia in humans is the small intestine, from diet, luminal bacterial activity, and deamination of glutamine in enterocytes. It is disposed of from the system, mainly in the liver, through the urea cycle. Physiologically, ammonia plays a minor role in acid-base homeostasis. It is the critical molecule implicated in the pathogenesis of hepatic encephalopathy. Liver disease is the most common cause of hyperammonemia, while others include urea cycle defects, infections, and drugs. The diagnostic utility of ammonia in liver diseases has met with increasing skepticism but holds good in urea cycle defects. Additionally, the accuracy of ammonia assay depends on a myriad of patient and technical factors, making the test unreliable if not performed meticulously. Most scientific societies currently fall short of recommending ammonia for diagnostic purposes in chronic liver disease. Despite this fact, ammonia continues to be one of the most frequently requested assays in patients with suspected hepatic encephalopathy, contributing to significant non-productive health expenditure. However, ammonia level does have a prognostic role in liver diseases, especially in acute liver failure. Ammonia-lowering strategies are the cornerstone of the management of hepatic encephalopathy. These strategies include medications that attenuate ammoniagenesis and ammonia scavengers. This review examines the role of ammonia in hepatic encephalopathy, its diagnostic and prognostic implications in liver diseases, challenges associated with ammonia assay, and current therapeutic strategies for ammonia-lowering in clinical practice.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 4","pages":"Pages 323-329"},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of removal of animal milk from the diet in functional dyspepsia: A cross-sectional study","authors":"Atilla Akpınar ,&nbsp;Koray Kochan ,&nbsp;Sercan Kiremitci ,&nbsp;Gulseren Seven ,&nbsp;Ali Tuzun Ince ,&nbsp;Hakan Senturk","doi":"10.1016/j.ajg.2024.07.010","DOIUrl":"10.1016/j.ajg.2024.07.010","url":null,"abstract":"<div><h3>Background and study aims</h3><div>We aimed to investigate the effect of removing milk and dairy products from diets on functional dyspepsia (FD) symptoms, as the aetiology remains unclear and new management approaches are needed.</div></div><div><h3>Patients and methods</h3><div>This cross-sectional cohort study included 120 patients, with a mean age of 42.5 ± 12.3, of whom 77 (64.2 %) were female, with FD diagnosed by the Rome IV criteria. Patients were divided equally into two groups: those who eliminated milk and dairy products from their diet under the advice of a dietician without medical treatment and those who did not. The severity of symptoms was assessed using the gastrointestinal symptom rating scale (GSRS) at the beginning and end of a one-month period.</div></div><div><h3>Results</h3><div>The restricted and unrestricted diet groups showed no significant differences in age, body mass index, symptom frequency and duration, weight changes, FD subtype, and gastroscopy results (p &gt; 0.05). The diet group had more female patients (p = 0.01) and higher GSRS scores at the beginning (p = 0.01) but similar scores at the end of the study (p = 0.99). After one month, both groups had improved GSRS scores (p = 0.01), but the diet group had a more significant decrease in total symptom scores (p = 0.01) and in 7 of the 15 subsets (p &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>Of the 120 FD patients who followed up for one month, 60 who removed milk products had a more significant reduction in GSRS symptom score and 7 of the 15 symptom subset scores than 60 patients receiving an unrestricted diet.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 4","pages":"Pages 390-398"},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hsa_circ_0008667 promotes progression and improves the prognosis of gastric cancer by inhibiting miR-9-5p","authors":"Wei Ding ,&nbsp;Zhengliang Li ,&nbsp;Xiaojing Liu ,&nbsp;Jundong Wang ,&nbsp;Jiaxi Wang ,&nbsp;Guoxiang Jiang ,&nbsp;Haizhou Yu ,&nbsp;Tuya Wang","doi":"10.1016/j.ajg.2024.09.002","DOIUrl":"10.1016/j.ajg.2024.09.002","url":null,"abstract":"<div><h3>Background and study aim</h3><div>Gastric cancer (GC) is one of the most common gastrointestinal tumors characterized by aggressive development and poor prognosis. Circular RNAs (circRNAs) have been used as prognostic biomarkers and therapeutic targets in many cancers, including GC. Hsa_circ_0008667 is differentially expressed in GC; however, its function and clinical significance remained unelucidated. Therefore, this study aimed to investigate the role and significance of hsa_circ_0008667 in GC and its potential as a biomarker and therapeutic target of GC.</div></div><div><h3>Patients and methods</h3><div>Through quantitative reverse-transcription real-time PCR, hsa_circ_0008667 expression in GC tissues and cells were analyzed, followed by statistical analyses to assess the clinical significance. Cell Counting Kit-8 and Transwell assays were performed to examine the effects of hsa_circ_0008667 silencing on GC cell growth and metastasis. Additionally, correlation analysis was performed to assess the relationship between hsa_circ_0008667 and miR-9-5p, which was further validated through luciferase reporter assay.</div></div><div><h3>Results</h3><div>Hsa_circ_0008667 was considerably upregulated and tightly correlated with lymph node metastasis and the tumor–node–metastasis stage, which was predictive of poor prognosis in patients with GC. Hsa_circ_0008667 silencing suppressed GC cell proliferation, migration, and invasion. Furthermore, hsa_circ_0008667 negatively regulated miR-9-5p expression. MiR-9-5p downregulation enhanced GC malignancy and reversed hsa_circ_0008667 knockdown-mediated GC suppression.</div></div><div><h3>Conclusion</h3><div>The findings of this study suggest hsa_circ_0008667 to be a prognostic biomarker and tumor promoter of GC via miR-9-5p modulation.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 4","pages":"Pages 349-355"},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142511001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High frequency of anti-Saccharomyces cerevisiae antibodies in chronic hepatitis C","authors":"Mariam Ghozzi ,&nbsp;Amani Mankai ,&nbsp;Fatma Mechi ,&nbsp;Zeineb Ben Chedly ,&nbsp;Ouafa Kallala ,&nbsp;Sarra Melayah ,&nbsp;Abdelhalim Trabelsi ,&nbsp;Ibtissem Ghedira","doi":"10.1016/j.ajg.2024.07.013","DOIUrl":"10.1016/j.ajg.2024.07.013","url":null,"abstract":"<div><h3>Background and study aim</h3><div>Chronic hepatitis C (CHC) is a liver disease caused by the hepatitis C virus. Anti-<em>Saccharomyces cerevisiae</em> (<em>S. cerevisiae</em>) antibodies (ASCA) are frequently reported in autoimmune diseases but rarely in viral infections. We aimed to determine the frequency of ASCA in adult patients with CHC.</div></div><div><h3>Patients and methods</h3><div>Eighty-eight patients with CHC and 160 healthy blood donors were included in this study. ASCA-IgG and IgA levels were determined using enzyme linked immunosorbent assay. For statistical analysis, we used open EPI version 3 as software. Correlations were determined by Spearman’s test using IBM® SPSS® Statistics.</div></div><div><h3>Results</h3><div>ASCA (IgG or IgA) were present in 31.8 % of patients and in 3.7 % of controls (<em>p</em> &lt; 10⁻⁶). ASCA-IgG and ASCA-IgA were more frequent in patients with CHC than in healthy subjects (23.9 % vs. 3.1 %; <em>p</em> &lt; 10⁻⁵ and 9.1 % vs. 0.6 %; <em>p</em> = 0.002, respectively). In patients, mean levels of ASCA-IgG and IgA were significantly higher than in controls (9.95 ± 11.78 U/mL vs. 2.28 ± 2.86 U/mL, <em>p</em> &lt; 10⁻⁶ and 5.96 ± 7.69 U/mL vs. 0.56 ± 0.12 U/mL, <em>p</em> &lt; 10⁻⁶; respectively). In patients with CHC, the mean level of ASCA-IgG was significantly higher than that of ASCA-IgA (9.95 ± 11.78 U/mL vs. 5.96 ± 7.69 U/mL, <em>p</em> = 0.008).</div></div><div><h3>Conclusion</h3><div>The frequency of ASCA was significantly higher in patients with CHC than in healthy controls.</div></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 4","pages":"Pages 378-382"},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal manifestations in a cohort of pediatric patients with inflammatory bowel disease","authors":"Afroditi Kourti ,&nbsp;Chrysoula Kosmeri ,&nbsp;Aikaterini Chira ,&nbsp;Ino Kanavaki ,&nbsp;Efstathios Stefos ,&nbsp;Periklis Foukas ,&nbsp;Smaragdi Fessatou","doi":"10.1016/j.ajg.2024.05.002","DOIUrl":"10.1016/j.ajg.2024.05.002","url":null,"abstract":"<div><h3>Background and study aims</h3><p>Renal involvement in inflammatory bowel disease is rather uncommon. This study aims to describe the spectrum of renal involvement in pediatric patients with IBD and reduce delay in detection and management.</p></div><div><h3>Patients and methods</h3><p>This is a retrospective study of the renal function of all patients, aged &lt;18 years, who have been followed for IBD in our pediatric gastroenterology department from January 2019 till January 2023.</p></div><div><h3>Results</h3><p><span><span>From the 75 IBD patients included in this study 16 % had renal manifestations. The urinalysis revealed </span>proteinuria<span><span> in 7 patients, proteinuria and hematuria<span><span> in 3 and proteinuria and glycosuria<span> in 2 patients. All 12 patients with abnormal urinalysis underwent further investigation in order to determine the cause of renal damage and the results are as follows: 2 patients had glomerulonephritis and in other 2 patients renal damage was due to medication adverse effect, 1 had pyelonephritis<span> in combination with chronic active tubulointerstitial nephritis and another 1 had </span></span></span>thin basement membrane disease. Three patients had IBD-related dependent renal involvement and 1 resulted in </span></span>chronic renal failure due to </span></span>amyloidosis.</p></div><div><h3>Conclusions</h3><p>It is important for all clinicians to be aware of the possibility of renal manifestations in IBD patients for the early diagnosis and prevention of these manifestations and complications.</p></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 3","pages":"Pages 284-287"},"PeriodicalIF":1.1,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between fibrosis-4 score and microvascular complications in patients with type 2 diabetes mellitus","authors":"","doi":"10.1016/j.ajg.2024.04.001","DOIUrl":"10.1016/j.ajg.2024.04.001","url":null,"abstract":"<div><h3>Background and study aims</h3><p><span>Nonalcoholic fatty liver disease is the most prevalent </span>chronic liver disease<span><span><span> globally and is linked to augmented susceptibility to type 2 diabetes mellitus (DM), cardiovascular disease, and </span>microvascular complications<span> inherent to DM, such as nephropathy, </span></span>neuropathy<span>, and retinopathy<span>. The fibrosis-4 (FIB-4) scoring system, a noninvasive tool, is useful for predicting the extent of liver fibrosis across diverse pathologies. This study aimed to assess the potential predictive role of FIB-4 scores in microvascular complications associated with diabetes.</span></span></span></p></div><div><h3>Patients and methods</h3><p><span><span><span>The medical records of patients with type 2 DM admitted to our </span>endocrinology clinic between February 2019 and December 2020 were retrospectively evaluated. Parameters including demographic attributes, fasting </span>blood glucose<span>, glycated hemoglobin, aspartate aminotransferase, </span></span>alanine aminotransferase, thrombocyte levels, and microvascular complications were recorded. The FIB-4 score was computed, and patients were categorized based on these scores (&lt;1.3 and ≥ 1.3).</p></div><div><h3>Results</h3><p><span><span>The analysis included 312 patients with a median age of 60 (50–68 years); 39.7 % were men. The median duration of diabetes was 10 years (5–20 years), and the median FIB-4 score was 0.93 (0.63–1.34). Neuropathy, nephropathy, and retinopathy were observed in 50.6 %, 31.4 %, and 34 % of the patients, respectively. Although the FIB-4 score did not differ significantly between patients with and without </span>neuropathy or retinopathy, patients with nephropathy exhibited higher FIB-4 scores. Notably, patients with FIB-4 scores ≥ 1.3 demonstrated a significantly higher prevalence of nephropathy. </span>Logistic regression analysis demonstrated that higher FIB-4 scores were significantly associated with an increased risk of nephropathy.</p></div><div><h3>Conclusion</h3><p>The FIB-4 score is a cost-effective and straightforward tool with potential applicability in predicting nephropathy in individuals with type 2 DM.</p></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 3","pages":"Pages 269-274"},"PeriodicalIF":1.1,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140892529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudomelanosis of the duodenum and stomach","authors":"","doi":"10.1016/j.ajg.2024.02.002","DOIUrl":"10.1016/j.ajg.2024.02.002","url":null,"abstract":"<div><p><span>Pseudomelanosis duodeni is characterized by endoscopic findings of black or black-brown speckled pigmentation<span><span> in the duodenal mucosa, usually diagnosed via biopsy. This report presents a case of a 75-year-old male presented with left </span>lower abdominal pain<span><span>, change in bowel habits, and </span>decreased appetite<span>. Gastroduodenoscopy and biopsies of the duodenum and </span></span></span></span>antrum lead to the diagnosis of pseudomelanosis duodeni.</p></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 3","pages":"Pages 320-322"},"PeriodicalIF":1.1,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease","authors":"","doi":"10.1016/j.ajg.2024.03.006","DOIUrl":"10.1016/j.ajg.2024.03.006","url":null,"abstract":"<div><h3>Background and study aims</h3><p><span><span>The infliximab </span>biosimilar<span> CT-P13 was the first biosimilar </span></span>drug targeting tumor necrosis factor-α. However, its efficacy and safety in real-world clinical situations have remained insufficient. Therefore, we aimed to verify the efficacy and safety of CT-P13 in bio-naïve patients with Crohn’s disease.</p></div><div><h3>Patients and methods</h3><p>This retrospective multicenter study compared the remission rate<span> at week 54 between patients with Crohn’s disease who were treated with originator infliximab or CT-P13. Endoscopic and laboratory findings were assessed in both groups. A total of 184 (156 originator and 28 CT-P13) patients were analyzed. Of these, 138 originator users and 19 biosimilar users completed 54-week administration.</span></p></div><div><h3>Results</h3><p>The clinical remission rates in patients taking originator infliximab of CT-P13 at week 54 were 92.5 % and 100 %, respectively. The endoscopic scores of each group significantly decreased from baseline at week 54 in both groups, and the mucosal healing rate at week 54 was 53 % and 64 %, respectively. Laboratory data including C-reactive protein, serum albumin<span>, and hemoglobin significantly improved from baseline to week 14 and 54 in both groups. Adverse events were observed more frequently in the CT-P13 group (25 % vs. 4.5 %, p = 0.0015), but severe adverse events were rare in both groups.</span></p></div><div><h3>Conclusion</h3><p>The efficacy and safety of CT-P13 were comparable with those of originator infliximab in bio-naïve patients with Crohn’s disease evaluated by clinical, endoscopic, and laboratory findings. This study establishes the needed groundwork for the development of a strategy for treatment with biologics in patients with Crohn’s disease.</p></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 3","pages":"Pages 257-262"},"PeriodicalIF":1.1,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of the laminin genes family and its relationship to prognosis in pancreatic carcinoma","authors":"ShengJie Dai ,&nbsp;Hongru Kong ,&nbsp;Yang Ja ,&nbsp;Liqi Bao ,&nbsp;Chengchao Wang ,&nbsp;Lei Qin","doi":"10.1016/j.ajg.2024.07.006","DOIUrl":"10.1016/j.ajg.2024.07.006","url":null,"abstract":"<div><h3>Background and study aims</h3><p>Laminin is an extracellular matrix molecule that is the major component of the basement membrane and plays a key role in regulating various processes. However, the association between the laminin gene family and the prognosis of pancreatic carcinoma has not been systematically investigated.</p></div><div><h3>Patients and methods</h3><p>The role of the laminin gene family in pancreatic cancer was evaluated using data from the TCGA database. The effects of different expressions of members of the laminin gene family on pancreatic cancer survival were compared, and their primary cellular roles were examined. The effects of different expressions of positive family genes on proliferation, metastasis, and invasion, as well as EMT and ferroptosis in pancreatic cancer, were also examined.</p></div><div><h3>Results</h3><p>Based on univariate and multifactorial analysis of pancreatic cancer patients, LAMA3 was identified as an independent prognostic factor for overall survival in pancreatic cancer. LAMA3 was found to be enriched in the actin cytoskeleton, P53 signaling pathway, adhesion molecule junctions, pentose phosphate pathway, and regulatory differences in the cell cycle and focal adhesion. Additionally, high expression of LAMA3 was found to promote cancer proliferation, invasion, and metastasis, facilitate the EMT process, and inhibit ferroptosis.</p></div><div><h3>Conclusions</h3><p>Our results identified LAMA3 was associated with the prognosis of patients with pancreatic cancer and may serve as a prognostic biomarker for pancreatic cancer.</p></div>","PeriodicalId":48674,"journal":{"name":"Arab Journal of Gastroenterology","volume":"25 3","pages":"Pages 306-314"},"PeriodicalIF":1.1,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1687197924000686/pdfft?md5=ff180492a3408579551251fa9ef12d85&pid=1-s2.0-S1687197924000686-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}